Skip to main content

Advertisement

SpringerLink
Log in

Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Information on the use of ankylosing spondylitis (AS) therapies in clinical practice is a key factor in decision making, as more efficient treatments may involve substantial savings while maintaining the clinical benefits for the patient. Objective To assess the mean annual doses and associated costs of the three main anti-tumour necrosis factor agents used in Spanish daily clinical practice in ankylosing spondylitis patients and to correlate these costs with disease activity. Setting This retrospective, observational study included adult ankylosing spondylitis patients over a 4-year period that had been treated for at least 6 months with adalimumab, etanercept or infliximab at two University Hospitals in Spain. Methods Disease activity was estimated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores at the start of anti-tumour necrosis factor (anti-TNF) therapy and in the last visit or whenever the drug was switched. Mean costs were estimated for a 52-week horizon from the delivered doses registered by pharmacy records. Outcomes were the doses and costs of anti TNFs administered to each patient, and the BASDAI score. Results A total of 119 patients (137 cases) were included (28 cases treated with adalimumab, 48 cases with etanercept and 61 with infliximab). Mean doses of adalimumab and etanercept were 92.8 and 88.8 % of the initially prescribed doses, respectively, while the mean dose of infliximab administered was 102 %. There were no statistical differences among treatments in terms of clinical effectiveness. Associated mean patient-year costs were significantly higher in the infliximab group (€14,235), compared to the other treatments [adalimumab €11,934; etanercept €10,516; (P < 0.05)]. Conclusion In certain ankylosing spondylitis patients, doses and associated costs of biological therapies can be reduced while controlling disease activity. Mean doses used in our clinical practice vary from the recommended doses and are significantly lower for adalimumab and etanercept than for infliximab. These differences impact directly on associated patient-year costs, and, thus, on treatment efficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Khan MA. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am. 1992;18(1):1–10.

    PubMed  Google Scholar 

  2. van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012;4(6):413–22.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Reveille JD. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol. 2006;18(4):332–41.

    Article  CAS  PubMed  Google Scholar 

  4. Thomas GP, Brown MA. Genomics of ankylosing spondylitis. Discov Med. 2010;10(52):263–71.

    PubMed  Google Scholar 

  5. Chorus AM, Miedema HS, Boonen A, Van Der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis. 2003;62(12):1178–84.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Kiltz U, van der Heijde D. Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S108–11.

    CAS  PubMed  Google Scholar 

  7. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4–11.

    PubMed  Google Scholar 

  8. Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum. 2001;45(5):424–9.

    Article  CAS  PubMed  Google Scholar 

  9. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61(5):429–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896–904.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8–18.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.

    CAS  PubMed  Google Scholar 

  13. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(3):316–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204714.

    PubMed  Google Scholar 

  15. Rémy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29(1):96–103.

    PubMed  Google Scholar 

  16. Fitzcharles MA, Clayton D, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol. 2002;29(12):2525–30.

    CAS  PubMed  Google Scholar 

  17. Lee J, Noh JW, Hwang JW, Oh JM, Kim H, Ahn JK, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29(10):1149–54.

    Article  PubMed  Google Scholar 

  18. Moghimi J, Sheikhvatan M, Semnani V. The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int. 2012;32(8):2271–4.

    Article  CAS  PubMed  Google Scholar 

  19. Tenga G, Goeb V, Lequerre T, Bacquet-Deschryver H, Daragon A, Pouplin S, et al. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine. 2011;78(1):50–5.

    Article  CAS  PubMed  Google Scholar 

  20. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.

    Article  PubMed  Google Scholar 

  21. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. The Spanish version of the BASDAI is reliable and correlates with disease activity in patients with ankylosing spondylitis. Rev Esp Reumatol. 2004;31(6):372–8.

    Google Scholar 

  22. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67(3):340–5.

    Article  CAS  PubMed  Google Scholar 

  23. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6.

    Article  CAS  PubMed  Google Scholar 

  24. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67(3):346–52.

    Article  CAS  PubMed  Google Scholar 

  25. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.

    Article  PubMed  Google Scholar 

  26. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.

    Article  PubMed  Google Scholar 

  27. The Association of British Pharmaceutical Industry. The vision for real world data—harnessing the opportunities in the UK. Demonstrating value with real world data. White paper: September 2011. http://www.abpi.org.uk/our-work/library/industry/Documents/Vision-for-Real-World-Data.pdf.

  28. Lee SH, Lee YA, Hong SJ, Yang HI. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol. 2008;27(2):179–81.

    Article  PubMed  Google Scholar 

  29. Navarro-Compan V, Moreira V, Ariza-Ariza R, Hernandez-Cruz B, Vargas-Lebron C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30(7):993–6.

    Article  PubMed  Google Scholar 

  30. Paccou J, Bacle-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol. 2012;39(7):1418–23.

    Article  CAS  PubMed  Google Scholar 

  31. Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford). 2007;46(8):1320–8.

    Article  CAS  Google Scholar 

  32. Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford). 2007;46(8):1338–44.

    Article  CAS  Google Scholar 

  33. Neilson AR, Sieper J, Deeg M. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology (Oxford). 2010;49(11):2122–34.

    Article  Google Scholar 

  34. Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E. The burden of ankylosing spondylitis in Spain. Value Health. 2008;11(3):408–15.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank the patients, as well as the participating investigators, support staff and the Rheumatology Departments of Gregorio Marañón University General Hospital and La Princesa University Hospital. The authors also thank Jose María Bellón Cano, from the Institute for Health Research Gregorio Marañón, for his support in statistical analysis.

Funding

This study evolved as part of an educational grant funded by Pfizer, which had no involvement either in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication. Editorial assistance was provided by Content Ed Net and Medical Statistics Consulting S. L. and funded by Pfizer.

Conflicts of interest

The authors have no conflicts of interests related to the content of the present manuscript.

Author information

Authors and Affiliations

  1. Pharmacy Department, Gregorio Marañón University General Hospital, Doctor Esquerdo 46, 28007, Madrid, Spain

    Vicente Escudero-Vilaplana, Nicolás Trovato-López & María Sanjurjo-Sáez

  2. Pharmacy Department, La Princesa University Hospital, Madrid, Spain

    Esther Ramírez-Herráiz, Estefanía Alañón-Plaza & Alberto Morell-Baladrón

  3. Rheumatology Department, La Princesa University Hospital, Madrid, Spain

    Rosario García-Vicuña

  4. Rheumatology Department, Gregorio Marañón University General Hospital, Madrid, Spain

    Luis Carreño-Pérez

Authors
  1. Vicente Escudero-Vilaplana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esther Ramírez-Herráiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Estefanía Alañón-Plaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicolás Trovato-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosario García-Vicuña
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luis Carreño-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alberto Morell-Baladrón
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. María Sanjurjo-Sáez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicente Escudero-Vilaplana.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Escudero-Vilaplana, V., Ramírez-Herráiz, E., Alañón-Plaza, E. et al. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Int J Clin Pharm 37, 808–814 (2015). https://doi.org/10.1007/s11096-015-0124-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-015-0124-1

Keywords

Search

Navigation